||Sheraton Portland Airport Hotel
||Saturday, June 8, 2013 12:30PM
||To register scroll down.
"Rethinking SIHD" explores several key issues regarding the diagnosis and management of stable ischemic heart disease (SIHD). It has been a long-held belief that SIHD is a myocardial ischemic condition associated with episodes of angina occurring when oxygen demand exceeds coronary blood flow. However, there is a growing recognition that SIHD actually constitutes a spectrum of pathophysiologic and clinical manifestations, which encompasses stenotic (macrovascular), non-stenotic (microvascular), and nonvascular aspects of myocardial ischemia.
This new understanding, together with the latest Practice Guidelines for diagnosis and management of SIHD, have reframed the essential elements of diagnosis, ischemic risk assessment, and treatment options for improving clinical outcomes and reducing ischemic symptoms. This refined understanding about the pathobiology of SIHD and its range of presentations will lead to improved diagnoses of SIHD patients with atypical symptoms. These insights are also reinforced by key clinical trial data and the Practice Guidelines, which call for guideline-directed medical therapy (GDMT) as first-line therapy for SIHD, rather than preemptive revascularization. This program also addresses the point that treatment options should be based on the ischemic burden, with revascularization as an option in patients with a moderate to extensive ischemia who remain symptomatic despite GDMT.
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Professor of Medicine, Harvard Medical School
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular Program
Brigham and Women's Hospital and VA Boston Healthcare System
Senior Investigator, TIMI Study Group
David A. Morrow, MD, MPH
Director, Levine Cardiac Intensive Care Unit
Brigham & Women's Hospital
Senior Investigator, TIMI Study Group
Associate Professor of Medicine
Harvard Medical School
The target audience for this initiative is community cardiologists, interventional cardiologists, and other professionals who treat patients with stable ischemic heart disease (SIHD).
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Describe the latest thinking about the spectrum of pathophysiology and clinical manifestations of SIHD, which encompasses both stenotic (macrovascular) and non-stenotic (microvascular) mechanisms of myocardial ischemia
- Identify the key findings from pivotal trials that guide the optimal selection of medical and invasive therapies for the individual patient
- Recognize the core management goals of SIHD that are the underpinnings for new appropriateness criteria and guidelines for management of SIHD
- Demonstrate the ability to apply new performance measures to the management of SIHD, including annual monitoring of symptoms and levels of activity that induce symptoms
|Lunch & CME Program:
||12:30pm – 1:30pm
Physicians – This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians – The Potomac Center for Medical Education designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test or evaluation, please email firstname.lastname@example.org.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
Method of Participation
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME/CE certificate will be emailed following the program or distributed onsite.
There are no fees associated with this program.
Event staff will be glad to assist you with any specials needs (e.g. physical, dietary, etc.). Please email email@example.com at least 5 days prior to the program.
Jointly Sponsored By
Jointly sponsored by Potomac Center for Medical Education and Rockpointe
Supported by an educational grant from Gilead Sciences, Inc
By clicking the Registration Button below you are agreeing that you have read and understood the CME/CE Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.
Click here to view the presentation slides from this CME-certified series held at select American College of Cardiology state chapter meetings during the Fall of 2013.